Provided by Tiger Trade Technology Pte. Ltd.

Warren Buffett holdings

3,267.70
+19.160.59%
Number of Gainers:17
Number of Losers:18
Number of Flat:- -
PE:- -
High:3,272.93
Open:3,248.94
Low:3,214.14
Close:3,248.53
Volume:292.48M
Turnover:40.13B
Market Cap:11.61T
Float Cap:11.04T

Loading ...

How Amazon's Stock Can Fight Off the AI Threat and Soar 46%

Dow Jones
·
Sep 30

Synopsys up on over $1 Billion Chip Design Licensing Deal with Amazon

Reuters
·
Sep 30

UPS announces launch of UPS Secure Commerce

TIPRANKS
·
Sep 30

Bank of America Posts Update to Financial Calendar

Reuters
·
Sep 30

Mastercard Partners with Cloudflare to Boost Visibility into AI-Driven Payment Activity

Reuters
·
Sep 30

Yuyu Pharma CEO Attends Amazon Accelerate 2026 in Seattle

Reuters
·
Sep 30

Amazon: Alexa+ Gets a Dedicated Hub on Fire TV with Smarter Reasoning When Recommending Movies and Shows

THOMSON REUTERS
·
Sep 30

Synopsys, - Amazon to Expand Use of Synopsys Application-Optimized Silicon Ip and AI Technologies

THOMSON REUTERS
·
Sep 30

Synopsys, Inc. - Adopting Amazon Ec2 & Cloud Storage Services, as Well as Amazon Bedrock to Build and Deploy AI Applications and Agents

THOMSON REUTERS
·
Sep 30

Synopsys, - Co and Amazon to Collaborate on AI Across Silicon-to-System Engineering Workflows

THOMSON REUTERS
·
Sep 30

Yuyu Pharma Brings Ari's Purrfect to Amazon Accelerate 2026

THOMSON REUTERS
·
Sep 30

Healthequity Appoints Moody’s CFO NoÉMIE Heuland to Board of Directors

THOMSON REUTERS
·
Sep 30

Progress Software Advances Domo Magic ETL and Expands Governed AI Capabilities

GlobeNewswire
·
Sep 30

Press Release: HealthEquity Appoints Moody's CFO Noémie Heuland to Board of Directors

Dow Jones
·
Sep 30

UBS Sticks to Its Hold Rating for Apple (AAPL)

TIPRANKS
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

American Express Announces R$ 0.3280546420 Per Unit Dividend for 4Q 2026, Payable Nov. 19

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30